Bicycle Therapeutics Stock Forecast, Price & News

Bicycle Therapeutics (NASDAQ:BCYC) Frequently Asked Questions

Is Bicycle Therapeutics a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bicycle Therapeutics stock.
View analyst ratings for Bicycle Therapeutics or view top-rated stocks.

How has Bicycle Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Bicycle Therapeutics' stock was trading at $17.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BCYC shares have increased by 208.5% and is now trading at $54.60.
View which stocks have been most impacted by COVID-19.

Are investors shorting Bicycle Therapeutics?

Bicycle Therapeutics saw a increase in short interest in October. As of October 29th, there was short interest totaling 443,400 shares, an increase of 44.5% from the October 14th total of 306,900 shares. Based on an average daily volume of 319,300 shares, the days-to-cover ratio is currently 1.4 days.
View Bicycle Therapeutics' Short Interest.

When is Bicycle Therapeutics' next earnings date?

Bicycle Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Bicycle Therapeutics.

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics plc (NASDAQ:BCYC) released its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.61) by $0.02. The firm earned $4.33 million during the quarter, compared to analysts' expectations of $5.29 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 48.12% and a negative net margin of 562.38%.
View Bicycle Therapeutics' earnings history.

What price target have analysts set for BCYC?

8 Wall Street analysts have issued 1-year price targets for Bicycle Therapeutics' stock. Their forecasts range from $58.00 to $85.00. On average, they anticipate Bicycle Therapeutics' share price to reach $68.25 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price.
View analysts' price targets for Bicycle Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Bicycle Therapeutics' key executives?

Bicycle Therapeutics' management team includes the following people:

• Kevin Lee, Chief Executive Officer & Executive Director (LinkedIn Profile)
• Lee H. Kalowski, President & Chief Financial Officer (LinkedIn Profile)
• Michael Skynner, Chief Operating Officer
• Nicholas Keen, Chief Scientific Officer (LinkedIn Profile)
• Dominic Smethurst, Chief Medical Officer

Who are some of Bicycle Therapeutics' key competitors?

Some companies that are related to Bicycle Therapeutics include HUTCHMED (HCM), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Mawson Infrastructure Group (WIZP), Ultragenyx Pharmaceutical (RARE), Perrigo (PRGO), I-Mab (IMAB), Cerevel Therapeutics (CERE), Allakos (ALLK), Arvinas (ARVN), Ionis Pharmaceuticals (IONS), Karuna Therapeutics (KRTX), Apellis Pharmaceuticals (APLS), 23andMe (ME) and Alkermes (ALKS).
View all of BCYC's competitors.

What other stocks do shareholders of Bicycle Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM), Agenus (AGEN), Applied Genetic Technologies (AGTC), Akero Therapeutics (AKRO) and Alector (ALEC).

When did Bicycle Therapeutics IPO?

(BCYC) raised $64 million in an IPO on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Bicycle Therapeutics' stock symbol?

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

Who are Bicycle Therapeutics' major shareholders?

Bicycle Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (5.93%), Point72 Asset Management L.P. (5.80%), AXA S.A. (0.71%), Verition Fund Management LLC (0.64%), Victory Capital Management Inc. (0.53%) and Morgan Stanley (0.52%). Company insiders that own Bicycle Therapeutics stock include Kate Bingham, Kevin Lee, Lee Kalowski, Nicholas Keen, Nigel Crockett, Pierre Legault, Plc Glaxosmithkline and Stephen B Alexander.
View institutional ownership trends for Bicycle Therapeutics.

Which major investors are selling Bicycle Therapeutics stock?

BCYC stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Janus Henderson Group PLC, Verition Fund Management LLC, Victory Capital Management Inc., Laurion Capital Management LP, Moody Aldrich Partners LLC, Advisor Group Holdings Inc., and Parkman Healthcare Partners LLC. Company insiders that have sold Bicycle Therapeutics company stock in the last year include Kate Bingham, Kevin Lee, Lee Kalowski, Nicholas Keen, Nigel Crockett, Pierre Legault, and Stephen B Alexander.
View insider buying and selling activity for Bicycle Therapeutics or view top insider-selling stocks.

Which major investors are buying Bicycle Therapeutics stock?

BCYC stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Altium Capital Management LP, Morgan Stanley, Bellevue Group AG, Two Sigma Advisers LP, Jump Financial LLC, Goldman Sachs Group Inc., and Woodstock Corp.
View insider buying and selling activity for Bicycle Therapeutics or or view top insider-buying stocks.

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bicycle Therapeutics' stock price today?

One share of BCYC stock can currently be purchased for approximately $54.60.

How much money does Bicycle Therapeutics make?

Bicycle Therapeutics has a market capitalization of $1.61 billion and generates $10.39 million in revenue each year. The company earns $-51.01 million in net income (profit) each year or ($2.89) on an earnings per share basis.

How many employees does Bicycle Therapeutics have?

Bicycle Therapeutics employs 2,020 workers across the globe.

What is Bicycle Therapeutics' official website?

The official website for Bicycle Therapeutics is www.bicycletherapeutics.com.

Where are Bicycle Therapeutics' headquarters?

Bicycle Therapeutics is headquartered at B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT.

How can I contact Bicycle Therapeutics?

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company can be reached via phone at 441223261503.